Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR‑780 iodide is a near-infrared (NIR) heptamethine cyanine dye with strong absorption and emission in the NIR region (maximum excitation wavelength around 777–780 nm). It is primarily used as a fluorescent probe for imaging applications and as a phototherapeutic agent. In cancer research, it serves as a photosensitizer in photodynamic therapy (PDT), where it generates reactive oxygen species upon irradiation to directly destroy cancer cells and enhance tumor immunogenicity. Additionally, its unique properties allow for selective accumulation in certain cell types such as human cancer stem cells via HIF‑1α/glycolysis-dependent mechanisms. The compound has also been incorporated into nanoparticle formulations for combined photothermal and chemotherapeutic strategies against tumors[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IR-780 iodide.